Natural Killer T cells Balancing the Regulation of Tumor Immunity /

Natural killer T (NKT) cells are CD1d-restricted T cells that respond to lipid, not protein, antigens presented by CD1d, which is a non-classical MHC class I-like molecule.  This relatively small but pivotal T cell population bridges the gap between innate and adaptive immunity by rapidly produce la...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Terabe, Masaki (Επιμελητής έκδοσης), Berzofsky, Jay A. (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York, 2012.
Έκδοση:1.
Σειρά:Cancer Drug Discovery and Development
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03558nam a22004815i 4500
001 978-1-4614-0613-6
003 DE-He213
005 20151107111224.0
007 cr nn 008mamaa
008 110920s2012 xxu| s |||| 0|eng d
020 |a 9781461406136  |9 978-1-4614-0613-6 
024 7 |a 10.1007/978-1-4614-0613-6  |2 doi 
040 |d GrThAP 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 614.5999  |2 23 
245 1 0 |a Natural Killer T cells  |h [electronic resource] :  |b Balancing the Regulation of Tumor Immunity /  |c edited by Masaki Terabe, Jay A. Berzofsky. 
250 |a 1. 
264 1 |a New York, NY :  |b Springer New York,  |c 2012. 
300 |a XII, 208 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Cancer Drug Discovery and Development 
505 0 |a Preface.-  Introduction: Mechanisms of NKT cell-mediated adjuvant activity and function of iPS-derived NKT cells -- Structure and Recognition of Antigens for Invariant NKT Cells -- Invariant NKT cell-based vaccine strategies -- Immune regulation of tumor immunity by NKT cells -- The Regulation of CD1d+ and CD1d- tumors by NKT Cells -- DC-based immunotherapy targeting NKT cells -- Therapeutic Approaches Utilising NKT Cells -- NKT Cells of Cancer Patients & How Models can Inform Therapeutic Plans -- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges -- Clinical trials with α-galactosylceramide (KRN7000) in advanced cancer -- Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer -- Index.  . 
520 |a Natural killer T (NKT) cells are CD1d-restricted T cells that respond to lipid, not protein, antigens presented by CD1d, which is a non-classical MHC class I-like molecule.  This relatively small but pivotal T cell population bridges the gap between innate and adaptive immunity by rapidly produce large amounts of many kinds of cytokines and by providing the T cell arm of the adaptive immune system a mechanism to detect lipid antigens. NKT cells also have both regulatory and effector functions and have been shown to play critical roles in the regulation of immune responses in many disease settings including cancer. Stimulating the protective functions of NKT cells while inhibiting the negative regulatory activity shows promise for the therapy of cancer and several approaches are in clinical trials.               This book reviews what we have learned about NKT cells during last two decades through functional studies in the context of tumor immunology, including clinical trials of NKT cell targeted therapy.  This knowledge should also be informative to understand the role of this underappreciated T cell population in many other fields outside of tumor immunology. 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Cancer Research. 
650 2 4 |a Pharmacology/Toxicology. 
700 1 |a Terabe, Masaki.  |e editor. 
700 1 |a Berzofsky, Jay A.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781461406129 
830 0 |a Cancer Drug Discovery and Development 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4614-0613-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)